Loop Genomics looks to displace Sanger sequencing with a massively parallel, low-cost long-read NGS approach

SAN JOSE, Calif., Aug. 4, 2020 /PRNewswire/ — Loop Genomics has come one step closer to replacing Sanger sequencing with NGS. Loop’s new product enables massively parallel multiplexing of colonies and cloned DNA’s into a single tube and sequencing them on NGS instruments, reducing the time and cost of sequencing cloned DNA. 

“The decades old practice of sequencing amplicons from colonies is still prohibitively expensive in high throughput setups,” says Tuval Ben Yehezkel PhD, CEO of Loop Genomics. “Labs are looking for affordable and scalable solutions for sequencing hundreds to thousands of clones at a time using NGS, but standard NGS preps are too expensive for high-throughput colony sequencing and Sanger sequencing is ill-suited for high-throughput sequencing.  Loop’s solution leapfrogs existing technology in terms of multiplexing ability and cost reduction. This is the solution that high-throughput labs have been waiting for to finally transition the sequencing of cloned DNA to NGS.”

Loop Genomics now offers this solution as both a clone sequencing service and a kit to be used by core facilities, service labs and labs engaged in high-throughput clone sequencing wanting to bring this technology in house.

“We are replacing the existing labor intensive, expensive, one clone at a time processing of cloned DNA with low price, high throughput, multiplexed NGS of cloned DNA.  We are very pleased with how many Synthetic Biology companies see the value of our method and have already adopted and validated our technology for this critical application in their space,” says Tuval Ben Yehezkel PhD, CEO and founder of Loop Genomics.

Notes to editors:
Founded in 2015, Loop Genomics is a San Francisco bay area company that commercializes technology for Next-Generation Sequencing.

CONTACT: Tony Lialin, 650-284-9732, tony@loopgenomics.com

View original content:http://www.prnewswire.com/news-releases/loop-genomics-looks-to-displace-sanger-sequencing-with-a-massively-parallel-low-cost-long-read-ngs-approach-301105889.html

SOURCE Loop Genomics

Staff

Recent Posts

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…

34 minutes ago

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

12 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

15 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

15 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

15 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

15 hours ago